Shionogi & Co., Ltd. (SGIOF)

Shionogi & Company Description

Shionogi & Co., Ltd. researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices.

It offers and develops drugs in the areas of infectious diseases, COVID-19, tumors, sclerosis, pomp, fragile X syndrome, and other diseases.

The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943.

Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Shionogi & Co., Ltd.

Country	Japan
Founded	1878
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	4,955
CEO	Isao Teshirogi

Contact Details

Address: 1-8, Doshomachi 3-chome Osaka, 541-0045 Japan
Phone	81 6 6202 2161
Website	shionogi.com

Stock Details

Ticker Symbol	SGIOF
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3347200002
SIC Code	2834

Key Executives

Name	Position
Dr. Isao Teshirogi Ph.D.	Chief Executive Officer, President and Representative Director
Takuji Fujiwara	Accounting and Finance Manager
Takeshi Shiota Ph.D.	Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics and Compliance Management Div.
Yoshimasa Kyokawa	Vice President of Corporate Communications and Secretary Office
Yoshihiro Furuya	Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office
Dr. John A. Keller Ph.D.	Senior Executive Officer, SVice President of Research & Development Supervisory Unit and Pharma. Tech. Research Div. and Director
Kazuhiro Hatanaka	Senior Executive Officer and Senior Vice President of Corporate Supervisory Unit
Akira Kato Ph.D.	Senior Executive Officer and Senior Vice President of Supply Supervisory Unit
Toshinobu Iwasaki Ph.D.	Senior Executive Officer and Senior Vice President of Healthcare Business Supervisory Unit
Masashi Deguchi Ph.D.	Corporate Officer and Senior Vice President of Sustainability Management Division